Effect of antisense oligodeoxynucleotide targeting survivin on growth of human gastric cancer cells

Authors

  • Lantao Xu Department of Gastroenterology, Fengxian District Central Hospital, Shanghai 201400

DOI:

https://doi.org/10.3329/bjp.v8i1.13337

Keywords:

Antisense, Apoptosis, Gastric cancer cell, Oligodeoxynucleotide, Survivin

Abstract

Our study investigated the effects of antisense oligodeoxynucleotide targeting survivin on human gastric cancer cells. Human gastric cancer cells were incubated with antisense oligodeoxynucleotide targeting survivin for pre-designed durations, and then the cell growth was observed under light and electronic microscopes. Electrophoresis of fractured DNA fragments was performed to detect the DNA distribution and telomere repeat amplification protocol (TRAP) was used for the detection of telomerase activity. Antisense oligodeoxynucleotide targeting survivin could induce the apoptosis of human gastric cancer cells which were characterized by plasma membrane blistering, chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies. Electrophoresis showed characteristic DNA ladder. Flow cytometry revealed hypo-diploid apoptosis peak before G1 phase and the telomerase activity was significantly inhibited. These results demonstrated antisense oligodeoxynucleotide targeting survivin can induce the apoptosis of gastric cancer cells to inhibit their proliferation.

Downloads

Download data is not yet available.
Abstract
2314
Download
566 Read
235

References

Altieri DC, Marchisio PC. Survivin apoptosis:an interloper between cell death and cell proliferation in cancer. Lab Invest. 2006; 79: 1327-33.

Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997; 3: 917-21.

Chang JT, Wong FH, Liao CT. Enzyme immunoassay for serum autoantibody to surviving and its findings in head-and-neck cancer patients. Clin Chem. 2009; 11: 1261-64.

Graeber TG, Osmanian C, Jacks T. Hypoxia-mediated selection of cells with dimished apoptotic in solid tumours. Nature 2005; 379: 88-91.

Grossman D, Kim PJ, Blanc-Brude OP. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of P53. J Clin Invest. 2006; 108: 991-99.

Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res. 2011; 11: 1474-82.

Mesri M, Wall NR, Li J. Cancer gene therapy using a surviving mutant adenovirus. J Clin Invest. 2010; 108: 981-90.

Miao GY, Lu QM, Zhang XL. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterol. 2010; 13: 1170-74.

Nagata S. Aoptosis by death factor. Cell. 2005; 88: 355-65.

Shinozawa I, Inokuchi K, Wakabayashi I. Disturbed expression of the anti-apoptosis gene,Survivin,and EPR-1 in hematological malignancies. Leuk Res. 2005; 24: 965-70.

Tanabe H, Yagihashi A, Tsuji N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer. 2006; 46: 299-304.

Tarnawski A, Pai R, Chiou SK, Chai J, Chu EC. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun. 2005; 334: 207-12.

Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 2006; 267: 1456-62.

Tsuji N, Furuse K, Asanuma F. Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased Survivin expression in breast cancer. Breast Cancer Res Treat. 2011; 87: 23-31.

Downloads

Additional Files

Published

2013-01-28

How to Cite

Xu, L. “Effect of Antisense Oligodeoxynucleotide Targeting Survivin on Growth of Human Gastric Cancer Cells”. Bangladesh Journal of Pharmacology, vol. 8, no. 1, Jan. 2013, pp. 73-77, doi:10.3329/bjp.v8i1.13337.

Issue

Vol. 8 No. 1 (2013)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).